Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject: A survey among Indian healthcare practitioners to understand In-Practice usage of tamsulosin and dutasteride in management of BPH patients with co-morbid conditions

Male lower urinary tract symptoms (LUTS) are one of the most common causes for consultation with a health care provider, and one of the most common causes of male LUTS is benign prostatic hyperplasia (BPH). Male LUTS is commonly divided into 3 different symptom categories: voiding or obstructive (hesitancy, slow stream, intermittency, incomplete emptying), storage or irritative (frequency, urgency, nocturia, urge urinary incontinence), and postmicturition (postvoid dribbling). Medical treatments of symptomatic BPH include: 5α-reductase inhibitors (5ARIs), α1-adrenergic antagonists, and the combination of a 5ARI and a α1-adrenergic antagonist. Tamsulosin is a selective α1A- and α1D-adrenoceptor antagonist indicated for the treatment of the signs and symptoms of BPH. Tamsulosin is effective in patients with mild to severe LUTS, patients with diabetes mellitus or those aged ≥65 years and does not interfere with the antihypertensive action of nifedipine, enalapril or atenolol. It has a tolerability profile similar to that of placebo (apart from a higher incidence of abnormal ejaculation, dizziness and rhinitis). Dutasteride is a potent, selective, irreversible inhibitor of type 1 and type 2 5α-reductase isoenzymes approved for the treatment of moderate to severe symptomatic BPH in men with an enlarged prostate. The combination of an alpha- blocker and a 5ARI is an effective treatment for patients with LUTS associated with demonstrable prostatic enlargement.

The current survey is planned among Indian healthcare practitioners to understand In- Practice usage of tamsulosin and dutasteride in management of BPH patients with co- morbid conditions.

As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.